2 July 2026
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026
Advising firms
Deal team
20 lawyers named in this releaseThe named deal team is part of full access
Full access opens the named team, the stated value and what it measures, the client and the counterparties, each with the sentence it was taken from.
Stated terms
The stated value, client and counterparties is part of full access
Full access opens the figure exactly as the release prints it, what that figure measures, the client and the counterparties, each with the sentence it came from.